Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 5/2018

01-10-2018 | Original Paper

β-Catenin gene promoter hypermethylation by reactive oxygen species correlates with the migratory and invasive potentials of colon cancer cells

Authors: Suhrid Banskota, Sadan Dahal, Eunju Kwon, Dong Young Kim, Jung-Ae Kim

Published in: Cellular Oncology | Issue 5/2018

Login to get access

Abstract

Purpose

Over half of the colon cancer patients suffer from cancer-related events, mainly metastasis. Loss of β-catenin activity has previously been found to facilitate cancer cell dissociation and migration. Here, we aimed to investigate whether epigenetic silencing of β-catenin induces human colon cancer cell migration and/or invasion.

Methods

HCT-116, Caco-2, HT-29 and SW620 cell migration and invasion capacities were assessed using scratch wound healing and Matrigel invasion assays, respectively. Confocal microscopy, qRT-PCR and Western blotting were performed to determine gene expression levels, whereas methylation-specific quantitative real-time PCR was used to assess the extent of β-catenin gene (CTNNB1) promoter methylation after treatment of the cells with TPA, hydrogen peroxide, 5-aza-2′-deoxycytidine and/or VAS2870.

Results

We found that treatment of HT-29 and Caco-2 cells (differentiated and low metastatic) with 12-O-tetradecanoyl phorbol-13-acetate (TPA; a tumor promoter) suppressed E-cadherin and β-catenin expression at both the mRNA and protein levels and, in addition, enhanced cell migration. Furthermore, we found that the CTNNB1 gene promoter methylation levels were higher in the more invasive HCT-116 and SW620 colon cancer cells than in HT-29 and CCD-841 (normal colon epithelial) cells. We also found that TPA or hydrogen peroxide induced CTNNB1 gene promoter methylation to a higher extent in HT-29 and CCD-841 cells than in HCT-116 and SW620 cells, and that the degree of CTNNB1 gene promoter methylation positively correlated with cell dissociation and migration. In addition, we found that co-treatment with 5-aza-2′-deoxycytidine (decitabine, a DNA methyl transferase inhibitor) and VAS2870 (a NADPH oxidase inhibitor) almost completely blocked the invasion of TPA-treated HT-29 and TPA-untreated HCT-116 and SW620 cells, and that these inhibitions surpassed those of the cells treated with decitabine or VAS2870 alone.

Conclusions

From our data we conclude that the extent of CTNNB1 gene promoter methylation by reactive oxygen species correlates with the migratory and invasive abilities of colon cancer cells. Our results suggest that epigenetic regulation of CTNNB1 may serve as a novel avenue to block colon cancer cell migration and invasion.
Literature
1.
M. Yilmaz, G. Christofori, Mechanisms of motility in metastasizing cells. Mol Can Res 8, 629–642 (2010)CrossRef
2.
R. Paduch, The role of lymphangiogenesis and angiogenesis in tumor metastasis. Cell Oncol 39, 397–410 (2016)CrossRef
3.
S. Schmidt, P. Friedl, Interstitial cell migration: Integrin-dependent and alternative adhesion mechanisms. Cell Tissue Res 339, 83–92 (2010)CrossRefPubMed
4.
5.
L. Lobastova, D. Kraus, A. Glassmann, D. Khan, C. Steinhäuser, C. Wolff, N. Veit, J. Winter, R. Probstmeier, Collective cell migration of thyroid carcinoma cells: A beneficial ability to override unfavourable substrates. Cell Oncol 40, 63–76 (2017)CrossRef
6.
7.
W. Birchmeier, J. Hülsken, J. Behrens, Adherens junction proteins in tumour progression. Cancer Surv 24, 129–140 (1995)PubMed
8.
T.T. Onder, P.B. Gupta, S.A. Mani, J. Yang, E.S. Lander, R.A. Weinberg, Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68, 3645–3654 (2008)CrossRefPubMed
9.
P.J. Morin, A.B. Sparks, V. Korinek, N. Barker, H. Clevers, B. Vogelstein, K.W. Kinzler, Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275, 1787–1790 (1997)CrossRefPubMed
10.
V. Korinek, N. Barker, P.J. Morin, D. Van Wichen, R. De Weger, K.W. Kinzler, B. Vogelstein, H. Clevers, Constitutive transcriptional activation by a β-catenin-Tcf complex in APC−/− colon carcinoma. Science 275, 1784–1787 (1997)CrossRefPubMed
11.
T. Li, Q. Lai, S. Wang, J. Cai, Z. Xiao, D. Deng, L. He, H. Jiao, Y. Ye, L. Liang, MicroRNA-224 sustains Wnt/β-catenin signaling and promotes aggressive phenotype of colorectal cancer. J Exp Clin Cancer Res 35, 21 (2016)CrossRefPubMedPubMedCentral
12.
X. Tian, Z. Liu, B. Niu, J. Zhang, T.K. Tan, S.R. Lee, Y. Zhao, D.C.H. Harris and G. Zheng, E-cadherin/β-catenin complex and the epithelial barrier. Biomed Res Int 2011, 567305 (2011)
13.
D. Kimelman, W. Xu, β-Catenin destruction complex: Insights and questions from a structural perspective. Oncogene 25, 7482–7491 (2006)CrossRefPubMed
14.
M.P.A. Ebert, J. Yu, J. Hoffmann, A. Rocco, C. Röcken, S. Kahmann, O. Müller, M. Korc, J.J. Sung, P. Malfertheiner, Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol 21, 1708–1714 (2003)CrossRefPubMed
15.
Y. Miao, L. Wang, X. Zhang, X. Xu, G. Jiang, C. Fan, Y. Liu, X. Lin, J. Yu, Y. Zhang, Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis. PLoS One 9, e112258 (2014)CrossRefPubMedPubMedCentral
16.
F. Coppedè, Epigenetic biomarkers of colorectal cancer: Focus on DNA methylation. Cancer Lett 342, 238–247 (2014)CrossRefPubMed
17.
J. Yuan, N.L. Luceño, B. Sander, M.M. Golas, Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells. Cell Oncol 40, 263–279 (2017)CrossRef
18.
M.S.G. Montani, M. Granato, C. Santoni, P. Del Porto, N. Merendino, G. D’Orazi, A. Faggioni, M. Cirone, Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells. Cell Oncol 40, 167–180 (2017)CrossRef
19.
M. Staberg, S.R. Michaelsen, R.D. Rasmussen, M. Villingshøj, H.S. Poulsen, P. Hamerlik, Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine. Cell Oncol 40, 21–32 (2017)CrossRef
20.
21.
22.
23.
S.H. Lin, J. Wang, P. Saintigny, C.-C. Wu, U. Giri, J. Zhang, T. Menju, L. Diao, L. Byers and J.N. Weinstein, Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial–mesenchymal transition. BMC Genomics 15, 1079 (2014)CrossRefPubMedPubMedCentral
24.
25.
D.C. Radisky, D.D. Levy, L.E. Littlepage, H. Liu, C.M. Nelson, J.E. Fata, D. Leake, E.L. Godden, D.G. Albertson, M.A. Nieto, Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436, 123–127 (2005)CrossRefPubMedPubMedCentral
26.
S. Banskota, S.C. Regmi, J.A. Kim, NOX1 to NOX2 switch deactivates AMPK and induces invasive phenotype in colon cancer cells through overexpression of MMP-7. Mol Cancer 14, 123 (2015)CrossRefPubMedPubMedCentral
27.
S. Banskota, S.C. Regmi, J. Gautam, P. Gurung, Y.J. Lee, S.K. Ku, J.H. Lee, J. Lee, H.W. Chang, S.J. Park, J.A. Kim, Serotonin disturbs colon epithelial tolerance of commensal E. Coli by increasing NOX2-derived superoxide. Free Radic Biol Med 106, 196–207 (2017)CrossRefPubMed
28.
K. Mori, M. Shibanuma, K. Nose, Invasive potential induced under long-term oxidative stress in mammary epithelial cells. Cancer Res 64, 7464–7472 (2004)CrossRefPubMed
29.
Q. Wu, X. Ni, ROS-mediated DNA methylation pattern alterations in carcinogenesis. Curr Drug Targets 16, 13–19 (2015)CrossRefPubMed
30.
M. Esteller, CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. Oncogene 21, 5427–5440 (2002)CrossRefPubMed
31.
R. Franco, O. Schoneveld, A.G. Georgakilas, M.I. Panayiotidis, Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett 266, 6–11 (2008)CrossRefPubMed
32.
S.O. Lim, J.M. Gu, M.S. Kim, H.S. Kim, Y.N. Park, C.K. Park, J.W. Cho, Y.M. Park and G. Jung, Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: Methylation of the E-cadherin promoter. Gastroenterology 135, 2128–2140 (2008)CrossRef
33.
T. Ikenoue, H. Ijichi, N. Kato, F. Kanai, T. Masaki, W. Rengifo, M. Okamoto, M. Matsumura, T. Kawabe, Y. Shiratori, Analysis of the β-catenin/T cell factor signaling pathway in 36 gastrointestinal and liver Cancer cells. Cancer Sci 93, 1213–1220 (2002)
34.
M. Ilyas, I. Tomlinson, A. Rowan, M. Pignatelli, W. Bodmer, β-Catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A 94, 10330–10334 (1997)CrossRefPubMedPubMedCentral
35.
D. Ahmed, P. Eide, I. Eilertsen, S. Danielsen, M. Eknaes, M. Hektoen, G. Lind, R. Lothe, Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2, e71 (2013)CrossRefPubMedPubMedCentral
36.
B.C. Park, D. Thapa, Y.S. Lee, M.K. Kwak, E.S. Lee, H.G. Choi, C.S. Yong, J.A. Kim, 1-furan-2-yl-3-pyridin-2-yl-propenone inhibits the invasion and migration of HT1080 human fibrosarcoma cells through the inhibition of proMMP-2 activation and down regulation of MMP-9 and MT1-MMP. Eur J Pharmacol 567, 193–197 (2007)CrossRefPubMed
37.
S.C. Regmi, S.Y. Park, S.K. Ku, J.A. Kim, Serotonin regulates innate immune responses of colon epithelial cells through Nox2-derived reactive oxygen species. Free Radic Biol Med 69, 377–389 (2014)CrossRefPubMed
38.
O. Tetsu, F. McCormick, Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422–426 (1999)CrossRefPubMed
39.
T. Brabletz, A. Jung, S. Dag, F. Hlubek, T. Kirchner, β-Catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 155, 1033–1038 (1999)CrossRefPubMedPubMedCentral
40.
B.P.L. Wijnhoven, W.N.M. Dinjens, M. Pignatelli, E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 87, 992–1005 (2000)CrossRefPubMed
41.
J. Theys, B. Jutten, R. Habets, K. Paesmans, A.J. Groot, P. Lambin, B.G. Wouters, G. Lammering, M. Vooijs, E-cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol 99, 392–397 (2011)CrossRefPubMedPubMedCentral
42.
43.
J.R. Graff, J.G. Herman, R.G. Lapidus, H. Chopra, R. Xu, D.F. Jarrard, W.B. Isaacs, P.M. Pitha, N.E. Davidson, S.B. Baylin, E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55, 5195–5199 (1995)PubMed
44.
A.O. Chan, S.K. Lam, B.C. Wong, W.M. Wong, M.F. Yuen, Y.H. Yeung, W.M. Hui, A. Rashid, Y.L. Kwong, Promoter methylation of E-cadherin gene in gastric mucosa associated with helicobacter pylori infection and in gastric cancer. Gut 52, 502–506 (2003)CrossRefPubMedPubMedCentral
45.
S.Y. Shin, C.G. Kim, E.H. Jho, M.S. Rho, Y.S. Kim, Y.H. Kim, Y.H. Lee, Hydrogen peroxide negatively modulates Wnt signaling through downregulation of β-catenin. Cancer Lett 212, 225–231 (2004)CrossRefPubMed
Metadata
Title
β-Catenin gene promoter hypermethylation by reactive oxygen species correlates with the migratory and invasive potentials of colon cancer cells
Authors
Suhrid Banskota
Sadan Dahal
Eunju Kwon
Dong Young Kim
Jung-Ae Kim
Publication date
01-10-2018
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 5/2018
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-018-0391-7

Other articles of this Issue 5/2018

Cellular Oncology 5/2018 Go to the issue

Original Paper

Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis

Original Paper

Stromal collagen type VI associates with features of malignancy and predicts poor prognosis in salivary gland cancer

Original Paper

Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation

Original Paper

Inositol-C2-PAF acts as a biological response modifier and antagonizes cancer-relevant processes in mammary carcinoma cells

Original Paper

Identification of an enhancer region within the TP63/LEPREL1 locus containing genetic variants associated with bladder cancer risk

Review

Interplay between NRF1, E2F4 and MYC transcription factors regulating common target genes contributes to cancer development and progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits